Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
2,226 stopped studies mapped to Malignant Digestive System Neoplasm and descendants · 91% state a reason
Over the 2,226 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT05546411 | A Trial of NIS793 With FOLFIRINOX in Pancreatic Cancer | Phase 2 | terminated | Sep 19, 2022 | Kimberly Perez, MD | Novartis, the drug manufacturer of NIS793, notified Dana Farber Cancer Institute that they are… | Drug supply |
| NCT04975256 | Adagrasib in Combination With BI 1701963 in Patients With Cancer (KRYSTAL 14) | Phase 1 | terminated | Jul 23, 2021 | Mirati Therapeutics Inc. | The decision was made to terminate this study to further enrollment, as of 08 March 2022. The… | Enrollment / accrual |
| NCT05555251 | BI-1607 in Combination with Trastuzumab in Subjects with HER2-positive Advanced Solid…(CONTRAST) | Phase 1 / Phase 2 | terminated | Sep 26, 2022 | BioInvent International AB | After the completion of phase IA, for business reasons it was decided to terminate the study. | Sponsor / business decision |
| NCT02878473 | Liver Transplantation for Early Intrahepatic Cholangiocarcinoma(LT for iCCA) | Phase 2 | terminated | Aug 25, 2016 | University Health Network, Toronto | Low accrual | Enrollment / accrual |
| NCT03549000 | A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in… | Phase 1 | terminated | Jun 7, 2018 | Novartis Pharmaceuticals | After review of data which showed low likelihood of efficacy in these patients Novartis decided to… | Safety / toxicity |
| NCT03329248 | QUILT-3.060: NANT Pancreatic Cancer Vaccine: Molecularly Informed Integrated… | Phase 1 / Phase 2 | terminated | Nov 1, 2017 | ImmunityBio, Inc. | Study halted prematurely and will not resume; participants are no longer being examined or… | Other (stated, no rule matched) |
| NCT04093557 | Improving Outpatient Colonoscopy Bowel Prep With the Orton Score | N/A | withdrawn | Sep 18, 2019 | University of Virginia | Not enough funding for research coordinator. | Funding |
| NCT03802747 | Immunotherapy Combined With Y-90 and SBRT for Colorectal Liver Metastases | Phase 1 | withdrawn | Jan 14, 2019 | University of Colorado, Denver | PI left the institution | Investigator |
| NCT04136769 | Preoperative/Neoadjuvant Therapy and Vascular Debranching Followed by Resection for…(PREVADER) | N/A | terminated | Oct 23, 2019 | Ulrich Ronellenfitsch, MD | Substantial delays in recruitment | Enrollment / accrual |
| NCT05164315 | Comparison Between Tailored Surgery Versus Total Mesorectal Excision in ycT2-3N0M0 | N/A | terminated | Dec 20, 2021 | Seoul National University Hospital | the high proportion of patients requiring TME(control group) suggests that proceeding with a… | Other (stated, no rule matched) |
| NCT02867839 | Adjuvant Chemotherapy With S-1 Plus Oxaliplatin Versus S-1 Alone in Locally Advanced…(RESCUE-GC) | Phase 3 | terminated | Aug 16, 2016 | Peking University Cancer Hospital & Institute | The number of patients enrolled was much less than expected | Enrollment / accrual |
| NCT04508140 | Study of BO-112 With Pembrolizumab for Colorectal or Gastric/GEJ Cancer With Liver… | Phase 2 | terminated | Aug 11, 2020 | Highlight Therapeutics | Low recruitment rate | Enrollment / accrual |
| NCT05427344 | Effectiveness of Aquatic Exercise on Fatigue, Neuropathy and Quality of Life Among Cancer… | N/A | withdrawn | Jun 22, 2022 | Tel Aviv University | The study was stopped because we were unable to recruit participants as planned. Therefore, it was… | Enrollment / accrual |
| NCT04985357 | Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor… | — | withdrawn | Aug 2, 2021 | Travera Inc | Abandoned prior to launch. | Other (stated, no rule matched) |
| NCT05418387 | A Social Support Intervention to Improve Treatment Among Hispanic Kidney and Liver Cancer… | N/A | withdrawn | Jun 14, 2022 | University of Arizona | The study will be withdrawn as the Principal Investigator, Ken Batai, left the institution prior to… | Investigator |
| NCT03145558 | TATE Versus TACE in Intermediate Stage HCC(TATE) | Phase 2 | terminated | May 9, 2017 | Teclison Ltd. | Landscape changed and the study population is no longer suitable for the study treatment. | Other (stated, no rule matched) |
| NCT02972034 | Study of MK-8353 in Combination With Pembrolizumab (MK-3475) in Participants With… | Phase 1 | terminated | Nov 23, 2016 | Merck Sharp & Dohme LLC | business reasons. | Sponsor / business decision |
| NCT05824559 | ME-344 and Bevacizumab in Previously Treated Metastatic Colorectal Cancer | Phase 1 | terminated | Apr 21, 2023 | MEI Pharma, Inc. | Company decision to wind down operations, close all clinical programs and evaluate strategic options | Sponsor / business decision |
| NCT06575725 | Botensilimab, Balstilimab and Regorafenib or Botensilimab and Balstilimab for the… | Phase 2 | withdrawn | Aug 28, 2024 | City of Hope Medical Center | Abandoned 9/23/24 | Other (stated, no rule matched) |
| NCT01101906 | A Randomized, Placebo-controlled, Double-blind Phase 2 Study With OSI-906 in Patients… | Phase 2 | terminated | Apr 12, 2010 | Astellas Pharma Inc | Company decided not to pursue the development of this drug in this patient population at this time | Sponsor / business decision |
| NCT02512692 | Gemcitabine-Cisplatin-90Y TARE for Unresectable Intrahepatic Cholangiocarcinoma | N/A | terminated | Jul 31, 2015 | Medical University of South Carolina | Enrollment closed by internal scientific review committee due to slow accrual. | Enrollment / accrual |
| NCT04258111 | IBI310 in Combination with Sintilimab in Patients with DNA Mismatch Repair Deficient… | Phase 2 | terminated | Feb 6, 2020 | Innovent Biologics (Suzhou) Co. Ltd. | After careful consideration, our company has decided to revise the overall development strategy for… | Sponsor / business decision |
| NCT03228043 | Apatinib for Resectable Colorectal Cancer | N/A | withdrawn | Jul 24, 2017 | Nanchong Central Hospital | It's not possible to complete in our hospital. | Other (stated, no rule matched) |
| NCT04933227 | A Study to Explore the Efficacy and Safety of Atezolizumab Plus Tiragolumab and… | Phase 2 | terminated | Jun 21, 2021 | Hoffmann-La Roche | Sponsor's decision to terminate the study after Stage 1; will not proceed with Stage 2. | Sponsor / business decision |
| NCT04840186 | EXtended CriteriA Treatment for LIver Metastases and Heavy Tumour BURden(EXCALIBUR3) | Phase 2 | suspended | Apr 9, 2021 | Oslo University Hospital | Not enough patients | Other (stated, no rule matched) |
| NCT06017297 | Neoadjuvant Tremelimumab and Durvalumab With Gem/Cis in Intrahepatic Cholangiocarcinoma(ESR-22-21719) | Phase 2 | withdrawn | Aug 30, 2023 | Georgetown University | Sponsor decision and challenges in finding eligible participants | Sponsor / business decision |
| NCT01318642 | Ganitumab in Locally Advanced Unresectable Adenocarcinoma of the Pancreas | Phase 2 | terminated | Mar 18, 2011 | NantBioScience, Inc. | NCT01318642: Planned independent DMC Interim review: ended for futility | Efficacy / futility |
| NCT03366012 | Rapid Assessment of Esophageal Adenocarcinoma Risk Test(REACT) | N/A | terminated | Dec 8, 2017 | Columbia University | Product recall | Other (stated, no rule matched) |
| NCT03512756 | A Randomized Phase 2/3 Multi-Center Study of SM-88 in Participants With Metastatic… | Phase 2 / Phase 3 | terminated | May 1, 2018 | Tyme, Inc | Sponsor's decision | Sponsor / business decision |
| NCT04937738 | Perioperative Chemotherapy in Gastric Cancer(PECORINO) | Phase 2 | terminated | Jun 24, 2021 | Ukrainian Society of Clinical Oncology | High rate of disease progression in XELOX arm | Other (stated, no rule matched) |
| NCT06448364 | A Study in Advanced/Metastatic Solid Tumors With the Study Medicine (PF-07329640) When…(LTbR) | Phase 1 | terminated | Jun 7, 2024 | Pfizer | Strategic business decision | Sponsor / business decision |
| NCT04989218 | Durvalumab and Tremelimumab With Platinum-based Chemotherapy in Intrahepatic…(ICC) | Phase 1 / Phase 2 | terminated | Aug 4, 2021 | University of Alabama at Birmingham | Slow accrual and study sponsor decision. | Enrollment / accrual |
| NCT04294784 | Nab-paclitaxel Plus PD-1 Inhibitor Versus Nab-paclitaxel As Second-line Treatment in… | Phase 2 | terminated | Mar 4, 2020 | Huazhong University of Science and Technology | slow recruitment forcing early suspension of screening and enrollment | Enrollment / accrual |
| NCT06034860 | Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With… | Phase 1 | terminated | Sep 13, 2023 | Molecular Templates, Inc. | Sponsor Termination | Other (stated, no rule matched) |
| NCT05076591 | IMM2902, a HER2/SIRPα Bispecific MAb-Trap Antibody-receptor Fusion Protein, in Patients… | Phase 1 | suspended | Oct 13, 2021 | ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | Due to a business decision resulting in the deprioritization of this project and with no safety… | Safety / toxicity |
| NCT03960060 | A Study of CCT301-59 CAR T Therapy in Adult Subjects With Recurrent or Refractory Solid…(CAR) | Phase 1 | terminated | May 22, 2019 | Shanghai PerHum Therapeutics Co., Ltd. | Adjustment of study strategy | Sponsor / business decision |
| NCT05056805 | An Exercise and Nutrition Monitoring Intervention (Pt Pal) for the Improvement of… | N/A | withdrawn | Sep 27, 2021 | M.D. Anderson Cancer Center | No participants enrolled. | Enrollment / accrual |
| NCT05610826 | Preoperative PRRT Versus Surgical Cytoreduction in Metastatic Pancreatic Neuroendocrine… | Phase 1 / Phase 2 | withdrawn | Nov 9, 2022 | University of Chicago | 0 enrollment | Enrollment / accrual |
| NCT03809624 | Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors…(PDL1x41BB) | Phase 1 | terminated | Jan 18, 2019 | Inhibrx Biosciences, Inc | Program terminated due to lack of meaningful efficacy signal. | Efficacy / futility |
| NCT02980029 | TVB 2640 for Resectable Colon Cancer Other Resectable Cancers; a Window Trial. | Phase 1 | terminated | Dec 2, 2016 | Mark Evers | Study was terminated by the PRMC for low accrual | Enrollment / accrual |
| NCT05012397 | Milademetan in Advanced/Metastatic Solid Tumors | Phase 2 | terminated | Aug 19, 2021 | Rain Oncology Inc | Sponsor Decision | Sponsor / business decision |
| NCT04923672 | Exercise Preconditioning with Cancer Surgeries(ExPre 01) | N/A | terminated | Jun 11, 2021 | University of Virginia | Company providing the computer application for exercise intervention suddenly closed for business | Sponsor / business decision |
| NCT03592264 | A Phase I/II Study of OBI-3424 in Subjects with Advanced Solid Tumors | Phase 1 / Phase 2 | terminated | Jul 19, 2018 | OBI Pharma, Inc | Little evidence of clinical activity in tumor types enrolled | Enrollment / accrual |
| NCT06199882 | SBRT Sequential Surufatinib Combined With Immunotherapy for Biliary Tract Carcinoma | Phase 2 | suspended | Jan 10, 2024 | Zhejiang Cancer Hospital | Patient recruitment difficulties | Enrollment / accrual |
| NCT04021277 | PS101-mediated ACT With Chemotherapy in Liver Metastases From Cancer of Gastrointestinal…(ACT) | Phase 1 | terminated | Jul 16, 2019 | EXACT Therapeutics AS | Business reason | Sponsor / business decision |
| NCT03207867 | A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and… | Phase 2 | terminated | Jul 5, 2017 | Novartis Pharmaceuticals | Sponsor decision | Sponsor / business decision |
| NCT04003896 | A Study to Evaluate Abemaciclib in Advanced Biliary Tract Carcinoma | Phase 2 | terminated | Jul 1, 2019 | Milton S. Hershey Medical Center | The manufacturer and funder Eli Lilly requested to terminate the study | Drug supply |
| NCT04536077 | Immunologic Effects of CDX-301 and CDX-1140 in Resectable Pancreatic Cancer Patients | Phase 2 | terminated | Sep 2, 2020 | Washington University School of Medicine | Celldex decision | Other (stated, no rule matched) |
| NCT01847495 | Evaluation of Low-dose Irinotecan and Cyberknife® SBRT to Treat Colorectal Cancer With… | N/A | withdrawn | May 7, 2013 | Wake Forest University Health Sciences | no patients enrolled | Enrollment / accrual |
| NCT04683939 | Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT141 in… | Phase 1 / Phase 2 | terminated | Dec 24, 2020 | BioNTech SE | Sponsor decision | Sponsor / business decision |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Dec 17, 2024source: clinicaltrials